This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
WEST LAFAYETTE, Ind., March 18, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced the company's management team will host an Investor and Analyst Day on Friday, March 22, 2013, from 9:30 a.m. to 1 p.m. EDT at The Setai Fifth Avenue in New York City.
Endocyte's senior management team will discuss the Company's strategic objectives, its programs for vintafolide and etarfolatide, its commercial strategies and its advancing pipeline of candidates targeting oncology and inflammation.
A live webcast of the event can be accessed by visiting the Investor Relations section of Endocyte's website at
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.
For additional information, please visit Endocyte's website at
CONTACT: Stephanie Ascher
Stern Investor Relations, Inc.
Martina Schwarzkopf, Ph.D.
Tony Russo, Ph.D.